Investigation Report on China Flurbiprofen Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333481|
|出版日期||內容資訊||英文 20 Pages
|Flurbiprofen的中國市場分析 Investigation Report on China Flurbiprofen Market, 2010-2019|
|出版日期: 2015年06月18日||內容資訊: 英文 20 Pages||
非類固醇消炎劑 (NSAID) ，其化學結構與類固醇完全不相同，不過，帶來同樣的抗發炎、抗風濕作用。還有由於比類固醇副作用都，使用於包含成藥的各種藥物。中國的NSAID市場，2014年達到50億人民幣以上。其中功效特別高的是Flurbiprofen，在中國上市以來，急速擴大著銷售額。2005年是200萬人民幣以下的市場規模，此後以64.9％年複合成長率(CAGR) 成長，2014年達4億6600萬人民幣。
Non-steroidal anti-inflammatory drug (NSAID) has a totally different chemical structure from steroids which have a similar anti-inflammatory antirheumatic action. NSAID can also provide analgestic and antipyretic effects with fewer side effects compared with steroids. NSAID, be it nonprescription one or prescription one, has been the most widely used in the clinic. The market size of NSAID in China exceeded CNY 5 billion in 2014. Some varieties of NSAID have become OTC drugs in China since they are very common in the clinic.
By inhibiting the activity of cyclooxygenase and thereby the synthesis of prostaglandins, flurbiprofen is able to have pain-killing and fever-reducing effects. As flurbiprofen's molecular structure involves a fluorine atom, it has stronger effects even in small doses compared with similar drugs. Flurbiprofen ranks first in NSAIDs.
After entering China, flurbiprofen develops fast with annual sales value rising from less than CNY 2 million in 2005 to CNY 466 million in 2014 and CAGR during this period reaching up to 64.9%. Currently, flurbiprofen in the Chinese market mainly come from the following two companies: Beijing Tide Pharmaceutical Co., Ltd and MIKASA SEIYAKU CO.,LTD, the former having the larger market share of 99% for sales value in 2014.
The market size of flurbiprofen in China is expected to keep growing in the next few years in China.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report:
6.1MIKASA SEIYAKU CO.,LTD KAKEGAWA FACTORY (JA)